Genetic risk and incident venous thromboembolism in middle-aged and older adults following Covid-19 vaccination

- 3 Authors: Junqing Xie¹, Albert Prats-Uribe¹, Maria Gordillo Maranon^{2,3}, Victoria Y. Strauss¹, Dipender
- 4 Gill^{4,5,6}, Daniel Prieto-Alhambra^{1,7}
- 5 1. Centre for Statistics in Medicine, NDORMS, University of Oxford
- 6 2. Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, Netherlands
- 7 3. Institute of Cardiovascular Science, University College London, London, UK
- Clinical Pharmacology and Therapeutics Section, Institute for Infection and Immunity, St
 George's, University of London, London, UK
- 10 5. Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- 11 6. Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK
- 12 7. Medical Informatics, Erasmus Medical Center University, Rotterdam

BACKGROUND

- 16 Covid-19 vaccination has been associated with an increased risk of venous thromboembolism (VTE).
- 17 However, it is unknown whether genetic predisposition to VTE is associated with an increased risk of
- 18 thrombosis following vaccination.

19 METHODS

1 2

13 14 15

- 20 Using data from the UK Biobank, which contains in-depth genotyping data and linked vaccination
- 21 and health outcomes information, we generated a polygenic risk score (PRS) using 299 genetic
- variants identified from a previous large genome-wide association study. We prospectively assessed
- associations between PRS and incident VTE after first and the second-dose vaccination separately.
- We conducted sensitivity analyses stratified by vaccine type (adenovirus- and mRNA-based) and
- using two historical unvaccinated cohorts. We estimated hazard ratios (HR) for PRS-VTE associations
- 26 using Cox models.

27 **RESULTS**

- 28 Of 359,310 individuals receiving one dose of a Covid-19 vaccine, 160,327 (44.6%) were males, and
- the mean age at the vaccination date was 69.05 (standard deviation [SD] 8.04) years. After 28- and
- 30 90-days follow-up, 88 and 299 individuals developed VTE respectively, equivalent to an incidence
- 31 rate of 0.88 (95% confidence interval [CI] 0.70 to 1.08) and 0.92 (95% CI 0.82 to 1.04) per 100,000
- 32 person-days. The PRS was significantly associated with a higher risk of VTE (HR per 1 SD increase in
- 33 PRS, 1.41 (95% CI 1.15 to 1.73) in 28 days and 1.36 (95% CI 1.22 to 1.52) in 90 days). Similar
- 34 associations were found after stratification by vaccine type, in the two-dose cohort and across the
- 35 historical unvaccinated cohorts.

CONCLUSIONS

36

- 37 The genetic determinants of post-Covid-19-vaccination VTE are similar to those seen in historical
- 38 data. This suggests that, at the population level, post-vaccine VTE has similar aetiology to
- 39 conventional VTE. Additionally, the observed PRS-VTE associations were equivalent for adenovirus-
- 40 and mRNA-based vaccines.

Introduction

42

- 43 Venous thromboembolism (VTE), primarily comprising deep vein thrombosis and pulmonary
- 44 embolism, is predominantly a disease of older age that affects nearly 10 million people worldwide
- 45 every year and frequently leads to morbidities and death. 1-3 Severe acute respiratory syndrome
- 46 coronavirus-2 (SARS-CoV-2) infection and coronavirus disease 2019 (Covid-19) have been recognised
- 47 as novel environmental triggers for VTE. Also, a number of spontaneous thromboembolic
- 48 complications were reported after Covid-19 vaccination, prompting the withdrawal of the Oxford-
- 49 AstraZeneca vaccine (ChAdOx1) from several markets or restrictions on its use. Later, emerging
- 50 evidence has suggested that VTE risks are substantially higher after SARS-CoV-2 infection than after
- 51 vaccination, regardless of vaccine type or brand.⁴
- Twins and family studies have shown that VTE is highly heritable, and a few clinical studies suggest
- that inherited thrombophilia can interact with various environmental risk factors, such as infectious
- 54 pneumonia.^{5,6} Additionally, many genetic variants associated with VTE and their effect sizes have
- been identified in large-scale genome-wide association studies (GWASs), making it possible to
- construct a polygenic risk score (PRS) to quantify genetic predisposition to the VTE trait.
- 57 The present study aimed to assess the association between a previously validated PRS for
- 58 conventional VTE and the post-Covid-19-vaccination VTE, where thrombotic events following post-
- 59 Covid-19-vaccination were hypothesised to be involved in distinctive pathobiological mechanisms.

Methods

60

- 62 UK Biobank
- 63 The UK Biobank (UKBB) is a prospective cohort of over 500,000 individuals recruited from England
- 64 (89%), Wales (7%) and Scotland (4%) between 2006 and 2010. Age at baseline enrolment ranged
- 65 from 40 to 69 years. Comprehensive information on demographics, socioeconomics, lifestyle factors,
- 66 physical metrics, and medical history were collected using a computer-based questionnaire and a
- 67 standardised portfolio of measurements. Genome-wide genotyping was performed using two
- 68 closely related purpose-designed arrays (the UK BiLEVE Axiom array and UK Biobank Axiom array).
- The genetic data have been quality controlled as described in previous studies. Over the follow-up,
- 70 health-related outcomes were captured through linkage to external data sources, including primary
- care, hospital inpatient and death data. Additional information is available at
- 72 https://www.ukbiobank.ac.uk/.
- 73 UKBB received ethical approval from the research ethics committee (National Health Service's
- 74 National Research Ethics Service North West (11/NW/0382), with all participants providing written
- 75 consent. This study was conducted under Application Number 65397.
- 76 Study population and design
- 77 For the vaccinated cohorts, all UKBB participants from England who received at least one dose of
- 78 BNT162b2 or ChAdOx1Covid-19 vaccines between December 2, 2020 (i.e., vaccines approval date in
- the UK) and September 31, 2021 were included. Eligible participants were followed from the
- vaccination date (index date) to outcome, death or the end of pre-specified follow-up windows (28
- 81 and 90 days), whichever came first. The participants from Wales or Scotland were not included due
- 82 to the lack of linkage to their vaccination records at the time of this analysis performed.

- 83 Two historical unvaccinated cohorts (named early-pandemic and pre-pandemic cohorts) were
- 84 constructed for comparison. For the early-pandemic cohort, the observational period started from
- 85 March 23 2020 (the announcement of the first national lockdown in the UK, index date) to
- 86 December 1 2020 (the last day before Covid-19 vaccines approval). In contrast, the pre-pandemic
- 87 cohort was followed one year earlier, from March 23 2019 (index date) to March 23 2020. In
- 88 addition, a Covid-19 infection cohort was curated with the date of infection as index date. People
- 89 with historical VTE at the study entry date were excluded for all study cohorts.

90 Polygenic risk score

- 91 We derived polygenic risk scores (PRS) for VTE as a weighted sum of risk alleles, using summary
- 92 statistics of 299 single nucleotide polymorphisms (SNPs) from a genome-wide association study
- 93 (GWAS) on VTE, which included the two clinically validated mutations: factor V Leiden p.R506Q and
- 94 prothrombin G20210A.9 Given that the selected GWAS sample included UKBB participants, we
- 95 conducted a sensitivity analysis using a newly generated alternative PRS based on a meta-analysis of
- 96 12 GWASs that did not cover UKBB participants. 10 We standardised the continuous PRS by z-
- 97 transformation to achieve a zero mean and standard deviation of 1 based on the entire UKBB
- 98 population.
- 99 Details on data manipulation and completed lists of SNPs included in the primary PRS and alternative
- 100 PRS are provided in the **sTable 1** and **sTable 2**.
- 101 Vaccination against covid-19
- 102 Vaccination status for UKBB participants was obtained from the linked primary care records
- provided by the two GP system suppliers: EMS and TPP (latest update: September 31, 2021). The
- 104 clinical codes used for the first and second dose of the Covid-19 vaccines were "1324681000000101"
- and "1324691000000104" in EMS (SNOMED CT) and "Y29e7" and "Y29e8" in TPP (READ v3),
- 106 respectively.

107 Venous thromboembolism

- 108 VTE, including pulmonary embolism and deep vein thrombosis, was captured from linked hospital
- 109 admission data from Hospital Episode Statistics, which contains all admissions in NHS hospitals in
- 110 England. Mortality was ascertained from linked national death registry data. We used the earliest
- date of VTE diagnosis as the event date. ICD-10 codes used to identify VTE and death are given in the
- 112 **sTable 3**.

113 Statistical analyses

- 114 We used Cox proportional-hazards models to assess the associations between the PRS and VTE
- outcome. We computed hazard ratios (HR) and their 95% confidence intervals (CI) with adjustment
- for age (at the index date), sex, and genetic ancestry (quantified by the first ten principal
- components). To identify the high genetic risk group, we tested three cut-off quantiles of PRS
- separately, including upper tertile (top 33%), quintile (top 20%), and the top 5% with the lower 66%
- as the reference. To ensure sufficient statistical power, this analysis was only performed in the 90-
- days follow-up window. We evaluated the balance of baseline characteristics within each
- 121 comparison pair according to a list of pre-specified covariates and adjusted for them in the Cox
- model if their absolute standardised mean difference was greater than 0.1. Considering varying VTE
- rates across the reference groups, we derived absolute risk increases (ARI) between high-risk and
- the reference PRS categories using the formula: (adjusted HR 1) * cumulative incidence in the
- 125 reference group.

- We calculated HRs for diabetes as a negative control outcome to examine the specificity of the PRS
- and the likelihood of potential residual confounding. Diabetes was chosen with considerations that it
- is a well-developed disease phenotype and not biologically related to the VTE PRS. In a sub-cohort
- where the EMIS system provided the primary care data, and vaccine types were recorded, separate
- 130 HRs were estimated among either ChAdOx1 or BNT162b2 vaccine recipients. Given that the
- heterologous prime-boost vaccination schedule in the UK is very uncommon¹¹ (with <1% in our
- data), no specific analyses in this regard have been performed.
- All the analyses were performed using PLINK1.9, QCTOOL v2, and R 4.1.2 software.

Results

134

- 136 Characteristics of vaccine recipients in UKBB
- 137 Of 380,822 UKBB participants eligible at the study entry (December 2, 2020), 378,662 (99.4%) and
- 138 376,416 (98.8%) received the first and second dose of Covid-19 vaccines, respectively, until the study
- end date (September 31, 2021) (Figure 1). For the one-dose cohort, the mean age was 69.05 years
- (standard deviation 8.04), and 160,327 (44.6%) were male (**Table 1**). A similar demographic profile
- was observed for the two-dose cohort (**Table 1**). The PRS approximated a normal distribution within
- each cohort (**sFigure 1**).
- 143 Association of the PRS with incident VTE
- During the follow-up periods, 88 and 299 individuals developed VTE within 28 and 90 days after first-
- dose vaccination (Table 2), equivalent to an incidence rate of 0.88 (95% CI 0.70 to 1.08) and 0.92
- 146 (95% CI 0.82 to 1.04) per 100,000 person-days. The unadjusted and adjusted HRs for VTE associated
- with the primary PRS were similar, with the latter being 1.41 (95% 1.15 to 1.73) per 1-SD increase in
- 148 PRS (1-SD-PRS) over 28-day follow-up and 1.36 (95% 1.22 to 1.52) over 90-days. The association
- between the PRS value and risk of VTE appears to be monotonic in nature (**sFigure 2**). After the
- second dose vaccination, the association between PRS and VTE was slightly attenuated (HR: 1.30
- 151 (95% 1.04 to 1.61) per 1-SD-PRS and 1.33 (95% 1.18 to 1.49) in the 28- and 90-days' follow-up
- window, respectively) (**Table 2**). Although there was a seemingly inverted U-shaped relationship
- 153 between the PRS and estimate of VTE risk following the second dose of vaccine, wide confidence
- intervals limit the reliability of this finding.
- 155 The observed rates and effect sizes of the observed associations were similar when comparing the
- 156 vaccinated and historical (unvaccinated) cohorts. Also, although absolute incidence rates of VTE in
- the infected cohort were substantially higher than those in other cohorts, the PRS-VTE association
- 158 persisted. A sensitivity analysis using an alternative PRS found similar although slightly weaker
- associations (**Table 2**).
- 160 Finally, no associations were observed for our proposed negative control outcome: the HR between
- 161 PRS and incident diabetes was 1.02 (95% 0.98 to 1.06) in the pre-pandemic and 0.98 (95% 0.93 to
- 1.04) in the early pandemic period (sTable 4).
- 163 Identification of high-risk group
- 164 Figure 2 presents HRs and ARI for VTE across three pre-defined high-risk categories. Briefly, relative
- risks increased with cut-offs from 33% to 5%, corresponding to HRs ranging from 1.67 (95% 1.33 to
- 2.09) to 2.10 (95% 1.39 to 3.18) in the one- and from 1.66 (95% 1.30 to 2.11) to 1.97 (95% 1.26 to
- 167 3.09) in the two-dose cohorts. Also, there was a linear increasing trend for absolute risk differences,

- with ARI of 0.45 (95% 0.22 to 0.74) to 0.76 (95% .27 to 1.51) and 0.40 (95% 0.19 to 0.67) to 0.59
- 169 (95% 0.16 to 1.28) in the one- and two-dose cohort respectively.
- 170 Different vaccine types
- Among 221,875 recipients with vaccine-type information available (138,059 received ChAdOx1 and
- 172 83,816 received BNT162b2), the observed PRS-VTE associations were similar across each dose and
- 173 follow-up window: HR ranged from 1.24 (95% CI 0.88 to 1.77) to 1.63 (95% CI 1.34 to 1.98) in
- 174 ChAdOx1 vaccinated cohorts, and from 1.20 (95% CI 0.82 to 1.76) to 1.38 (95% CI 0.99 to 1.93) in
- BNT162b2 vaccinated people (**Table 3**). Noticeably, the background VTE incidence rates in BNT162b2
- vaccinated cohorts were almost doubly higher than those in the ChAdOx1 vaccinated one, which was
- 177 expected given that the former vaccine was approved earlier in the UK and prioritised for older and
- 178 more vulnerable populations.¹²

Discussion

179

- Our study showed that a PRS for VTE could identify people at increased risk of VTE within 28 or 90
- days after receiving one or two doses of Covid-19 vaccines. Furthermore, the strength of the PRS
- association to post-Covid-19-vaccination VTE was similar to that seen for VTE before Covid-19
- 184 vaccination rollout.
- 185 The PRS used in the present study was developed and validated by Klarin .et al. Such study found a
- 186 2.5 to 3-fold increased risk of VTE associated with the highest 5% of the score in both case-control
- and prospective cohort study settings. PRecently, Marston et al. tested the performance of the PRS
- among cardiometabolic disease patients to predict VTE and observed a similar magnitude of effect
- 189 (2.7-fold for top 33 % vs bottom 66%). 13 Despite being aligned with these findings, the PRS-VTE
- associations estimated in our study were consistently weaker than the previously reported ones
- 191 even after the incorporation of the two clinically validated variants, possibly due to the discrepancies
- in defining VTE phenotypes between the original score deviation and this validation study. Also,
- 193 because our cohort only consisted of VTE naïve and relatively older participants, those with higher
- 194 genetic risk might have had a VTE in their earlier age and thus been excluded. As expected, our PRS
- was not associated with the proposed negative control outcome (incident diabetes), to some extent,
- demonstrating its specificity for VTE prediction.
- 197 The results of this study support several noteworthy conclusions. First, our data showed that
- individuals' genetic susceptibility to VTE was a risk factor for VTE among the Covid-19 vaccinated
- 199 population. Second, this genetic risk was independent of traditional risk factors such as old age,
- 200 obesity and comorbidity, as indicated by no associations between the PRS and baseline
- characteristics (**Table 1**). Third, by designing a historical comparison arm in the same population, our
- data suggest that clinically significant interactions between individuals' genetic background and
- 203 Covid-19 vaccination are unlikely, which has particular implications for patients with hereditary VTE
- 204 predisposing traits who are hesitant to be vaccinated because of concerns regarding related recent
- vaccine safety signals. Fourth, we identified 5% of people with more than 2-fold higher VTE risk by
- using this genetic score, it should be of public health relevance and can inform potential intervention
- policies given the absolute size of Covid-19 vaccinated population. Our analyses have some potential
- 208 limitations. First, VTE often presents variable clinical manifestations with challenging differential
- 209 diagnoses such as myocardial infarction and congestive heart failure.² Consequently, identification of
- 210 VTE in a real-world setting is likely subject to information bias, which typically drives risk estimates
- 211 towards the null. Second, we were not able to generate a parallel unvaccinated comparison group

212213

214

215

216217

218219

220

221

222

223

224

225226

227

228

229

230

231

232

233234

235

236

237

238

239

240

241

242

243

because more than 99% of UKBB participants had been vaccinated. However, we constructed a historical comparison cohort with similar characteristics to those vaccinated. Also, given the relatively short follow-up after vaccination, the long-term impact of the genetic factor remains to be determined. Third, although we also constructed a secondary PRS for VTE, the weights of each included SNP have not been previously validated, and their utility in a PRS remains unknown. Opportunely, it conferred consistent results as the primary PRS did, likely due to the fact that both PRSs included the factor V Leiden p.R506Q and prothrombin G20210A variants which are known causes of inherited thrombophilia predisposing to acute thrombotic syndromes^{14,15}. Fourth, the HR estimates for each vaccine type should be considered exploratory in nature due to evident differences in the baseline risk for VTE seen between people vaccinated with the two vaccines. Last, the generalizability of our findings should be tested in more diverse ethnic populations as more integrated data sources containing in-depth genetic, vaccination, and health information becomes available. This study benefits from the use of a large prospective cohort with comprehensive genetic, Covid-19 vaccination, Covid-19 infection status and VTE phenotype data linked at the individual level, the application of the state-of-the-art PRS, and robust analytic methods by designing multiple comparison groups and a negative control outcome. To our knowledge, this is the first study to show that individuals' who developed post-Covid19-vaccination VTE had a genetic predisposition to VTE, and that the association between the genetic risk factors and post-Covid19-vaccination VTE is similar to the association with conventional VTE. **Conclusions** A published PRS for VTE, constructed using common genetic variants with small effects on VTE, was associated with increased VTE risk following Covid-19 vaccination. This association was similar to that seen historically, both in pre-pandemic times and during the first year of the Covid-19 pandemic, before vaccines were available. Our data do not support a clinically meaningful interplay between genetic predisposition and Covid-19 vaccines on the occurrence of VTE events. These findings suggest that the clinical management of VTE among the vaccinated population should not be disturbed by the concern of gene-vaccine interaction, and that people at high genetic risk of VTE such as those with inherited thrombophilia might have a modest excess risk of VTE occurrence following vaccination.

244

245246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265266

267

268

269

270

271

272

273

274

275

276

277

278

279

Disclaimer The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organisations with which the author(s) is/are employed/affiliated. **Funding** Mr Xie is funded through Jardine-Oxford Graduate Scholarship and a titular Clarendon Fund Scholarship. DG is supported by the British Heart Foundation Research Centre of Excellence (RE/18/4/34215) at Imperial College London and by a National Institute for Health Research Clinical Lectureship (CL-2020-16-001) at St. George's, University of London. Prof Prieto-Alhambra is funded through an NIHR Senior Research Fellowship (grant SRF-2018-11-ST2-004), and received partial support from the Oxford NIHR Biomedical Research Centre. APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1]. **Conflicts of interest** Prof Prieto-Alhambra research group has received grants and advisory or speaker fees from Amgen, Astellas, AstraZeneca, Chiesi-Taylor, Johnson & Johnson, and UCB; and that Janssen, on behalf of Innovative Medicines Initiative-funded European Health Data Evidence Network and European Medical Information Framework consortiums and Synapse Management Partners, have supported training programs, open to external participants, organized by his department. DG is employed parttime by Novo Nordisk. **Ethical approval** All participants provided written informed consent at the UKBB cohort recruitment. This study received ethical approval from UKBB Ethics Advisory Committee (EAC) and was performed under the application of 65397. Data sharing Bonafide researchers can apply to use the UK Biobank dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. **Transparency declaration** The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted. **Contributors** D.P.A., J.Q.X., D.G were responsible for the study design. J.Q.X. did the data analyses, and A.P.U. checked the statistical codes. J.Q.X. and D.P.A. drafted the manuscript, and all co-authors reviewed and approved it for submission.

Figure 1: Flow chart of the study selection process




Table 1: Baseline characteristics by the genetic risk categories (one dose).

			High PRS groups	S
	Overall	Top 33%	Top 20%	Top 5%
Number	359,310	119,770	71,862	17,965
Demographics				
Age, mean (sd)	69.05 (8.04)	69.10 (8.01)	69.14 (8.02)	69.11 (8.02)
Sex, male (%)	160327 (44.6)	53178 (44.4)	31766 (44.2)	7909 (44.0)
BMI, mean (sd)	27.30 (4.69)	27.29 (4.69)	27.29 (4.69)	27.26 (4.69)
Socio-economic status, mean (sd)				
IMD (Indices of Multiple Deprivation)	17.18 (13.62)	17.00 (13.50)	16.91 (13.43)	16.71 (13.27)
Income score	0.11 (0.09)	0.11 (0.09)	0.11 (0.09)	0.11 (0.09)
Employment score	0.09 (0.06)	0.09 (0.06)	0.09 (0.06)	0.08 (0.06)
Health score	-0.11 (0.84)	-0.12 (0.84)	-0.13 (0.84)	-0.14 (0.84)
Education score	15.23 (15.84)	15.14 (15.75)	15.09 (15.74)	14.98 (15.70)
Housing score	19.76 (10.12)	19.64 (10.08)	19.58 (10.07)	19.47 (10.10)
Crime score	-0.06 (0.77)	-0.06 (0.77)	-0.07 (0.77)	-0.07 (0.78)
Living environmental score	18.28 (15.07)	18.15 (14.96)	18.08 (14.89)	17.93 (14.66)

Indices of Multiple Deprivation offer a more complex and detailed view of deprivation, based on more factors than the Townsend index. All scores has been scaled to 0 to 1, 0 to 100, or even distributions standardized around 0, with higher values indicating more deprived. Details of individual score has been described in the GOV.UK (https://www.gov.uk/government/collections/english-indices-of-deprivation).

Table 2: Association between the genetic score and incident venous thromboembolism in vaccinated and reference cohorts.

				Primary PRS		Secondary PRS
	Number of people	Number of cases	Incidence rate (95% CI)*	Un-adjusted hazard ratio (95% CI)\$	Adjusted hazard ratio (95% CI) \$	Adjusted hazard ratio (95% CI) \$
Vaccinated cohorts						
28 days after one dose	359,310	88	0.88 (0.70 to 1.08)	1.41 (1.15 to 1.73)	1.41 (1.15 to 1.73)	1.38 (1.13 to 1.70)
90 days after one dose	359,310	299	0.92 (0.82 to 1.04)	1.36 (1.22 to 1.52)	1.36 (1.22 to 1.52)	1.34 (1.20 to 1.50)
28 days after two doses	357,018	78	0.78 (0.62 to 0.97)	1.31 (1.05 to 1.63)	1.30 (1.04 to 1.61)	1.25 (1.00 to 1.55)
90 days after two doses	357,018	269	0.83 (0.74 to 0.96)	1.34 (1.19 to 1.50)	1.33 (1.18 to 1.49)	1.29 (1.15 to 1.46)
Historically unvaccinated cohorts						
Whole UKBB (Pre-pandemic)	391,752	1078	0.76 (0.71 to 0.80)	1.36 (1.29 to 1.45)	1.36 (1.28 to 1.44)	1.34 (1.26 to 1.42)
Whole UKBB (Early-pandemic)	387,829	846	0.80 (0.74 to 0.85)	1.35 (1.26 to 1.44)	1.34 (1.26 to 1.44)	1.27 (1.19 to 1.36)
Infected cohorts						
28 days after infection	24,700	155	25.6 (21.8 to 30.0)	1.29 (1.10 to 1.51)	1.32 (1.13 to 1.55)	1.32 (1.12 to 1.55)
90 days after infection	24,700	186	10.9 (9.4 to 12.6)	1.27 (1.10 to 1.46)	1.29 (1.12 to 1.49)	1.28 (1.11 to 1.48)

The pre-pandemic was defined as the period between March 23 2019, and March 23 2020. The early-pandemic was defined as the period between March 23 2020, and December 1 2020. The negative control outcome was incident diabetes.

PRS, polygenic risk score, * per 100,000 person-days, \$Per 1-SD increase of PRS.

Figure 2: 90-day cumulative incidence (A), hazard ratios (B) and absolute risk increases (C) of three pre-defined high genetic risk groups vs the reference.





Table 3: Exploratory analyses for different vaccine types.

	ChAdOx1			BNT162b2		
Cohorts	No. of cases/ people	Incidence rate (95% CI)*	Adjusted hazard ratio (95% CI) ^{\$}	No. of cases/ people	Incidence rate (95% CI)*	Adjusted hazard ratio (95% CI) ^{\$}
28 days after one dose	25 / 138059	0.65 (0.42 to 0.96)	1.45 (0.99 to 2.13)	33 / 83816	1.41 (0.97 to 1.98)	1.38 (0.99 to 1.93)
90 days after one dose	94 / 138059	0.76 (0.61 to 0.93)	1.63 (1.34 to 1.98)	99 / 83816	1.31 (1.07 to 1.60)	1.24 (1.02 to 1.50)
28 days after two doses	30 / 136002	0.79 (0.53 to 1.13)	1.24 (0.88 to 1.77)	26 / 80709	1.15 (0.75 to 1.69)	1.20 (0.82 to 1.76)
90 days after two doses	100 / 136002	0.82 (0.67 to 1.00)	1.53 (1.27 to 1.85)	87 / 80709	1.20 (0.96 to 1.48)	1.22 (1.00 to 1.51)


^{*} per 100,000 person-days, ${}^{\varsigma}$ Per 1-SD increase of PRS.

Supplementary materials:

sFigure 1: Distribution of polygenic risk score for venous thromboembolism



sFigure 2: The relationship between the PRS value and the risk (hazard ratio) of VTE.



sTable 1: Summary statistics for candidate SNPs used for constructing the main polygenic risk score (Main PRS_VTE).

Chr:Pos (GRCh37)	<u>Rsid</u>	Effect Allele	<u>Beta</u>
1:11910677	rs632793	G	0.0466
1:150388318	rs698915	Α	0.0561
1:166533517	rs764024	T	0.0502
1:168406710	rs111414961	Α	0.1183
1:168500034	rs72703796	G	0.2014
1:168572720	rs72705895	T	0.1313
1:168577239	rs12567872	T	0.0893
1:168619548	rs1933116	T	0.1724
1:168673803	rs611769	С	0.0562
1:168714137	rs10918970	T	0.0572
1:168729611	rs12117978	Α	0.2166
1:168812398	rs34258243	G	0.1015
1:168889373	rs78516619	G	0.6841
1:168909952	rs7526462	T	0.0714
1:168937072	rs113123846	G	0.4417
1:168960286	rs1322487	Α	0.046
1:168969254	rs35990973	Α	0.1057
1:169012124	rs1320969	G	0.0478
1:169014610	rs116140155	Α	0.2498
1:169031755	rs113079063	T	0.2356
1:169038856	rs12747018	T	0.0717
1:169064630	rs1200118	G	0.1111
1:169070213	rs1892091	С	0.0526
1:169079419	rs1358714	Α	0.0444
1:169086013	rs2143289	T	0.2335
1:169107377	rs7520186	T	0.0873
1:169276816	rs10732287	T	0.0916
1:169316610	rs10158131	G	0.0673
1:169318242	rs72702145	Α	0.1342
1:169463296	rs147474835	G	0.12
1:169463519	rs4656683	T	0.1781
1:169486141	rs966751	G	0.1142
1:169511555	rs6032	T	0.1351
1:169593113	rs3917862	G	0.2198
1:169620673	rs12075684	G	0.0534
1:169659128	rs185120584	T	0.5696
1:170051841	rs115476742	С	0.0857
1:170080014	rs12128208	С	0.1373
1:170174298	rs12144655	Α	0.0893
1:181031783	rs3936939	Α	0.0458

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
1:201882277	rs2644120	С	0.058
1:207282149	rs2842700	Α	0.1138
1:207285043	rs577695638	С	0.1708
1:230417394	rs3088075	Т	0.0798
1:248028780	rs79322592	Α	0.0517
1:248039451	rs3811444	С	0.0513
1:9341786	rs677665	T	0.0521
2:127934102	rs10198483	Α	0.0559
2:127979335	rs111736896	Α	0.0717
2:128133076	rs35293119	G	0.0442
2:128175875	rs1799809	G	0.072
2:128187428	rs67495946	С	0.0631
2:128398892	rs67076363	Α	0.0733
2:161845453	rs75145714	С	0.1264
2:178238316	rs4893934	G	0.0449
2:198894550	rs535527575	G	0.1319
2:198946551	rs6434955	G	0.0587
2:68530180	rs13013670	Т	0.0485
2:68619981	rs1867312	С	0.0585
3:126238371	rs11721316	Α	0.061
3:126276710	rs12636448	С	0.0456
3:150872174	rs75347181	Α	0.1323
3:150880908	rs3116549	С	0.0522
3:185234111	rs115110838	T	0.0649
3:194787481	rs116764841	T	0.0661
3:36140951	rs113114306	Т	0.1047
3:39240559	rs7622284	Т	0.0741
3:6084766	rs11712865	G	0.0799
3:77048575	rs6799348	G	0.1488
3:88354842	rs1841009	Т	0.0567
3:89250573	rs7374904	Α	0.0751
3:89679389	rs141912156	Т	0.1656
3:90390344	rs9858006	Α	0.0465
3:93518545	rs139156297	T	0.1588
3:93580976	rs9290378	Т	0.0509
3:94209055	rs9290227	T	0.0849
4:155251071	rs116333064	Α	0.1157
4:155424231	rs4323084	Т	0.1012
4:155432944	rs4547780	G	0.064
4:155450158	rs13435192	Т	0.1124
4:155474683	rs115999709	G	0.1456
4:155494926	rs79726896	G	0.1598

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
4:155513276	rs2070008	T	0.0975
4:155515486	rs1984906	G	0.0671
4:155538470	rs13130318	G	0.1984
4:155542926	rs59234924	G	0.1077
4:155544958	rs72681247	Т	0.2163
4:155553541	rs79201245	С	0.1462
4:187114479	rs10866290	С	0.0464
4:187130620	rs72646294	Α	0.1947
4:187136519	rs113435394	С	0.2091
4:187161283	rs551251712	С	0.2385
4:187169469	rs2203111	G	0.0901
4:187178014	rs3775303	Т	0.1486
4:187180115	rs4253333	G	0.0494
4:187190285	rs925452	Α	0.2681
4:187196853	rs4253414	С	0.1544
4:187200550	rs56810541	Т	0.1975
4:187205929	rs4253425	С	0.2399
4:187213360	rs72712610	Α	0.1509
4:187219599	rs56379917	Α	0.1638
4:187220894	rs13126546	Т	0.1142
4:187234735	rs72712626	G	0.1365
4:187240280	rs13137269	Т	0.0617
4:187267791	rs75440104	С	0.1177
4:187347217	rs7685922	С	0.054
4:79917638	rs140303646	T	0.218
5:143119511	rs325247	С	0.0439
5:172785895	rs12234072	G	0.0661
5:32831939	rs12656497	Т	0.0438
5:38708554	rs16867574	С	0.059
5:63916834	rs4700642	Α	0.0491
5:75992254	rs56347914	С	0.0843
6:147701133	rs9373523	G	0.06
6:169633335	rs11759438	С	0.0436
6:25531133	rs214057	С	0.0446
6:28436060	rs2531815	Т	0.047
6:29894392	rs1627764	G	0.0525
6:30639412	rs3094094	Α	0.0793
6:31092767	rs3095304	Т	0.0634
6:31239869	rs2074492	Т	0.051
7:151028181	rs11981586	С	0.0657
7:157763424	rs1347390	G	0.0515
8:102881195	rs118105926	Α	0.1379

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
8:106573309	rs7341574	T	0.0452
8:106590705	rs4541868	С	0.0876
8:108291878	rs4236786	С	0.0512
8:108340982	rs7004172	G	0.051
8:108347806	rs6991048	Т	0.0904
8:27810577	rs2685413	G	0.0608
8:27820792	rs10087301	Α	0.0632
8:30265541	rs117564659	G	0.1314
8:53204323	rs138757339	С	0.2102
8:78572803	rs17383689	G	0.0833
8:87143573	rs7812868	С	0.0621
9:116253293	rs189064188	Т	0.0804
9:124362398	rs146383320	Т	0.1278
9:135985796	rs3761824	С	0.0538
9:136025460	rs3888561	С	0.0559
9:136031918	rs7027827	Α	0.0729
9:136056956	rs10793953	G	0.0496
9:136062437	rs10441806	С	0.105
9:136069931	rs7039497	G	0.1081
9:136077004	rs11244032	С	0.0837
9:136080512	rs149189328	С	0.2669
9:136081319	rs11244035	Т	0.2223
9:136098498	rs28470788	Т	0.0723
9:136121303	rs7855466	T	0.1054
9:136124590	rs78755596	Α	0.2855
9:136128731	rs11244051	Α	0.384
9:136144593	rs66697526	G	0.1399
9:136145404	rs9411377	Α	0.308
9:136152070	rs8176634	G	0.1117
9:136152722	rs8176630	С	0.1382
9:136156064	rs55988407	G	0.1664
9:136156230	rs78590974	Т	0.2221
9:136157037	rs557317	Α	0.1499
9:136177993	rs4962043	G	0.0607
9:136184782	rs9411395	G	0.1408
9:136184985	rs11791119	Т	0.1052
9:136185324	rs11789139	G	0.1669
9:136193356	rs76771223	G	0.1431
9:136212168	rs117119759	Α	0.2099
9:136226421	rs141397052	G	0.2259
9:136240304	rs3124755	С	0.1278
9:136255149	rs62575992	С	0.0967

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
9:136268084	rs3124747	A	0.0757
9:136270538	rs41302673	G	0.242
9:136277854	rs2285488	G	0.1007
9:136296530	rs149181677	Т	0.2461
9:136311017	rs652600	Α	0.0992
9:136323826	rs3094373	Α	0.2432
9:136343647	rs3094326	G	0.1027
9:136359182	rs736418	G	0.0556
9:136365146	rs28615587	Т	0.078
9:136382716	rs9802874	Α	0.0636
9:136390015	rs13300181	Α	0.0616
9:136397195	rs11507716	Т	0.0802
9:136509514	rs1611128	G	0.0495
10:121010256	rs10886430	G	0.1289
10:32397591	rs211416	Т	0.0684
10:45632668	rs2211163	Α	0.0724
10:71144324	rs2305196	Α	0.0555
10:71148728	rs12416320	G	0.1553
10:71153882	rs3793846	Т	0.0572
10:71181371	rs36054387	С	0.0729
10:71215107	rs137936874	G	0.2231
10:71218059	rs10998791	Α	0.0677
10:71245276	rs78707713	Т	0.2414
10:71262048	rs1665581	G	0.0771
10:71333897	rs12785008	С	0.0691
10:71346272	rs12783163	Α	0.0596
10:76189250	rs140438685	Α	0.2024
10:80898969	rs1769758	G	0.0436
10:96011865	rs1547643	G	0.0476
11:126300537	rs11600151	T	0.0793
11:32967270	rs563259534	T	0.1048
11:33247621	rs2061997	T	0.049
11:46559730	rs11038913	T	0.1126
11:46745003	rs5896	T	0.0668
11:46893108	rs2306029	T	0.0641
11:46896126	rs72897640	T	0.0672
11:47373425	rs2856656	С	0.3976
11:47794348	rs34953939	Α	0.0931
11:48865680	rs369876615	С	0.1184
11:50242788	rs117653193	Т	0.1049
11:51282525	rs11606922	С	0.1115
11:55436134	rs72910502	С	0.1161

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
11:56526894	rs543926510	С	0.1339
11:56735815	rs75348906	Α	0.0695
11:56875074	rs141798115	Т	0.2207
11:61489705	rs198428	Α	0.0464
11:61571348	rs174548	С	0.0842
11:61621611	rs73487492	Α	0.1034
11:73283937	rs12274057	T	0.0751
12:104147207	rs3751198	G	0.0491
12:111932800	rs7137828	С	0.0424
12:123861452	rs28413626	G	0.0739
12:32844798	rs61926202	Α	0.2109
12:39156743	rs137870902	T	0.2329
12:54734289	rs11170877	Α	0.0696
12:6071943	rs139727584	С	0.1076
12:6150824	rs183356	Α	0.1405
12:6160614	rs7135039	T	0.0781
12:6170645	rs78915411	G	0.0823
13:113787459	rs3211752	G	0.06
13:113808274	rs12858483	G	0.0588
14:100108918	rs12886724	G	0.0501
14:26690604	rs77398404	T	0.0794
14:66082793	rs2229678	С	0.1842
14:83281618	rs112089121	G	0.0752
14:92217670	rs61988257	Α	0.0603
14:94838142	rs112635299	Т	0.1463
15:43757184	rs190543502	Т	0.1973
15:43911751	rs115384559	Т	0.3853
15:44880783	rs148770227	С	0.1837
15:65114833	rs35204896	G	0.0738
15:66430422	rs74245462	Т	0.0503
15:96125226	rs17502085	Α	0.0525
16:1405044	rs116468525	Α	0.2059
16:81840709	rs34603417	Α	0.0456
16:81844607	rs9937779	С	0.0568
16:81870969	rs12445050	Т	0.1248
16:81874200	rs61374069	Α	0.0524
16:81896523	rs55909816	С	0.0437
16:81902990	rs4889419	G	0.0575
16:81915832	rs11150422	G	0.053
16:81971403	rs1071644	С	0.0475
16:81976177	rs16956040	С	0.0613
16:89265466	rs12926888	Α	0.0449

Chr:Pos (GRCh37)	Rsid	Effect Allele	Beta
17:1966457	rs1048483	T	0.0616
17:2172753	rs216181	A	0.072
17:43758898	rs57222984	G	0.0522
17:67081278	rs77542162	G	0.1932
17:7785590	rs78209469	T	0.0867
17:8393900	rs2270744	С	0.0447
18:74465347	rs62112094	Α	0.059
18:75283432	rs2032276	G	0.0435
18:8800723	rs631126	С	0.0579
19:10639312	rs8100818	Т	0.0483
19:10659971	rs11668544	G	0.1314
19:10688153	rs187758170	Α	0.1465
19:10734951	rs8110479	С	0.1131
19:10741622	rs12710257	G	0.1164
19:10898413	rs8107372	T	0.0515
19:17004049	rs1054533	T	0.0451
19:33896432	rs4805881	С	0.0544
19:3464793	rs142170418	С	0.1574
19:45426792	rs141622900	Α	0.1007
19:46268902	rs2341097	Т	0.0502
19:49241006	rs12981072	С	0.0469
19:55536595	rs1613662	Α	0.0818
19:7832001	rs874492	Α	0.0481
20:22672552	rs6137727	Α	0.0534
20:22938940	rs62204096	Α	0.1565
20:23000653	rs6076004	Т	0.0472
20:23077117	rs149439892	Α	0.1527
20:23170450	rs34397775	Α	0.084
20:23182559	rs6083037	Α	0.0798
20:32485961	rs6087538	С	0.0585
20:32523172	rs6059574	G	0.0479
20:33434252	rs56244533	Α	0.0567
20:33435161	rs17092148	G	0.0612
20:33451060	rs75627267	Т	0.1209
20:33587569	rs551986443	С	0.1488
20:33612647	rs564783003	С	0.1488
20:33733180	rs2050652	G	0.0564
20:33762035	rs2069946	С	0.1255
20:33772243	rs6060288	A	0.1178
20:33858772	rs6058218	G	0.0552
20:33895947	rs6058227	T	0.0813
20:34025983	rs143383	G	0.0482

Chr:Pos (GRCh37)	<u>Rsid</u>	Effect Allele	<u>Beta</u>
20:34562935	rs185663249	Α	0.1487
20:34712310	rs6141600	С	0.0482
22:42461918	rs2854827	G	0.0589
22:43107837	rs9620086	G	0.0609
22:44324730	rs738408	С	0.0566
1:169519049	rs6025	T	0.4031
11:46761055	rs1799963	Α	0.2741

sTable 2: Summary statistics for candidate SNPs used for constructing sensitive polygenic risk score (Secondary PRS_VTE).

SNPs (GRCh37)	Risk Allele	Allelic OR
rs6025	T	3.25
rs4524	T	1.20
rs2066865	Α	1.24
rs4253417	С	1.27
rs529565	С	1.55
rs1799963	Α	2.29
rs6087685	С	1.15
rs4602861	Α	1.20
rs78707713	T	1.28
rs2288904	G	1.19

sTable 3: ICD-10 codes for the identification of venous thromboembolism.

"I26"	Pulmonary embolism				
"1260"	Pulmonary embolism with mention of acute cor pulmonale				
"1269"	Pulmonary embolism without mention of acute cor pulmonale				
"1801"	Phlebitis and thrombophlebitis of femoral vein				
"1802"	Phlebitis and thrombophlebitis of other deep vessels of lower extremities				
"1803"	Phlebitis and thrombophlebitis of lower extremities, unspecified				
"181"	Portal vein thrombosis				
"182"	Other venous embolism and thrombosis				
"1820"	Budd-Chiari syndrome				
"1822"	Embolism and thrombosis of vena cava				
"1823"	Embolism and thrombosis of renal vein				
"1828"	Embolism and thrombosis of other specified veins				
"1829"	Embolism and thrombosis of unspecified vein				

sTable 4: Association between the polygenic risk score and the negative control outcome.

	Number of people	Number of cases	Incidence rate (95% CI)*	Adjusted hazard ratio (95% CI) \$
Diabetes				
Whole UKBB (Pre-pandemic)	373,207	2522	1.85 (1.78 to 1.93)	1.02 (0.98 to 1.06)
Whole UKBB (Early-pandemic)	368,112	1278	1.26 (1.20 to 1.34)	0.98 (0.93 to 1.04)

1. References

- 1 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. doi:10.1038/nrcardio.2015.83.
- 2 Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. *The Lancet*. 2021;398(10294):64-77. doi:10.1016/S0140-6736(20)32658-1.
- **3** White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107(23 Suppl 1):14-8. doi:10.1161/01.CIR.0000078468.11849.66.
- 4 Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ*. 2021;374:n1931. doi:10.1136/bmj.n1931.
- 5 Ribeiro DD, Lijfering WM, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Pneumonia and risk of venous thrombosis: results from the MEGA study. *Journal of Thrombosis and Haemostasis*. 2012;10(6):1179-1182. doi:10.1111/j.1538-7836.2012.04732.x.
- 6 Martinelli I, Stefano V de, Mannucci PM. Inherited risk factors for venous thromboembolism. *Nat Rev Cardiol*. 2014;11(3):140-156. doi:10.1038/nrcardio.2013.211.
- Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z.
- data.bris. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2 data.bris. https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v. Updated January 27, 2022. Accessed January 27, 2022.
- 9 Klarin D, Busenkell E, Judy R, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. *Nat Genet*. 2019;51(11):1574-1579. doi:10.1038/s41588-019-0519-3.
- 10 Germain M, Chasman DI, Haan H de, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. *American journal of human genetics*. 2015;96(4):532-542. doi:10.1016/j.ajhg.2015.01.019.
- 11 GOV.UK. Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020. https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020. Updated April 11, 2022. Accessed April 11, 2022.
- **12** GOV.UK. UK COVID-19 vaccines delivery plan. https://www.gov.uk/government/publications/uk-covid-19-vaccines-delivery-plan/uk-covid-19-vaccines-delivery-plan. Updated March 13, 2022. Accessed March 13, 2022.
- Marston NA, Melloni GEM, Gurmu Y, et al. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. *Circ Genom Precis Med*. 2020;14(1):e003006. doi:10.1161/CIRCGEN.120.003006.
- 14 Ridker PM. Ethnic Distribution of Factor V Leiden in 4047 Men and Women. JAMA. 1997;277(16):1305. doi:10.1001/jama.1997.03540400055031.
- Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. *JAMA*. 2009;301(23):2472-2485. doi:10.1001/jama.2009.853.